Animal Stem Cell Therapy Market – Great Growth Opportunities for the Market in the Coming Year | TMR Research Study – BioSpace

Advances in the stem cell therapy sector have been phenomenal over the years. Its assistance in curing humans of various diseases and disorders has generated expansive advancements. These advancements are not just limited to humans. Stem cell therapy has also acquired a prominent place in the veterinary sector.

The influence of animal stem cell therapy for the treatment of various animals for diverse diseases and disorders is growing rapidly. Therefore, this factor may help the global animal stem cell therapy market to generate exponential growth across the forecast period of 2019-2029. Stem cells help in the replacement of neurons affected by stroke, Parkinsons disease, spinal cord injury, Alzheimers disease, and others.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6816

This animal stem cell therapy market report has extensive information on various aspects associated with bringing growth. Important factors such as emerging trends, mergers and acquisitions, and the regional scenario of the animal stem cell therapy market have been analyzed and included in the report. The stakeholders can derive a treasure of information from this report. This report also includes a scrutinized take on the COVID-19 impact on the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Competitive Prospects

The competitive landscape of the animal stem cell therapy market can be described as mildly fragmented. With a considerable chunk of players, the animal stem cell therapy market is surrounded by substantial competition. Research and development activities form an important part of the growth landscape because they help gain novel insights.

Activities such as mergers, acquisitions, joint ventures, collaborations, and partnerships form the foundation of the growth of the animal stem cell therapy market. These activities help manufacturers to gain influence and eventually help in increasing the growth rate of the animal stem cell therapy market. Prominent participants in the animal stem cell therapy market are Magellan Stem Cells, Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc., Celavet Inc., VETSTEM BIOPHARMA, and VetCell Therapeutics.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6816&ltype=S

Animal Stem Cell Therapy Market: Key Trends

Infections are scaling up among animals at a rapid rate. The alarming increase is proving fatal for many animals. Therefore, to avoid such incidences and treat existing diseases and disorders, animal stem cell therapy is being applied seamlessly. Hence, this aspect may bring great growth opportunities for the animal stem cell therapy market.

Developments have been observed across the animal stem cell therapy market for long. Autologous adipose-derived mesenchymal stem cells are gaining traction for successfully resolving a range of issues in animals. These stem cells help in treating ligament and tendon injuries to a certain extent. The strengthening influence of this stem cell type in companion animals is also proving to be a prominent growth prospect for the animal stem cell therapy market.

Recent research has also found that stem cell-derived CC exosomes showed improved recovery from myocardial infarction (MI) among pigs. Such developments assure promising growth for the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Regional Analysis

The animal stem cell therapy market is spread across North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. The animal stem cell therapy market may derive significant growth from North America. The escalating awareness regarding animal stem cell therapy may attract profound growth. Strengthening research and development activities in the region regarding animal stem cell therapy is further expanding the growth prospects.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6816

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

View original post here:
Animal Stem Cell Therapy Market - Great Growth Opportunities for the Market in the Coming Year | TMR Research Study - BioSpace

Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia -…

Gosselies, Belgium, 5 October 2020, 7am CEST BONE THERAPEUTICS(Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, Link Health Pharma Co., Ltd (Link Health) and Shenzhen Pregene Biopharma Company, Ltd (Pregene) today announce the signing of an exclusive license agreement for the manufacturing, clinical development and commercialization of Bone Therapeutics allogeneic, off-the-shelf, bone cell therapy platform ALLOB in China (including Hong Kong and Macau), Taiwan, Singapore, South Korea, and Thailand.

Under the agreement, Bone Therapeutics is eligible to receive up to 55 million in development, regulatory and commercial milestone payments including 10 million in upfront and milestone payments anticipated in the next 24 months. Bone Therapeutics is also entitled to receive tiered double-digit royalties on annual net sales of ALLOB. Bone Therapeutics retains development and commercialization rights to ALLOB in all other geographies outside of those covered by this agreement. As a result, Bone Therapeutics will continue to concentrate on its development and commercialization plans for ALLOB in the US and Europe and novel innovative cell-based products globally.

This collaboration between Bone Therapeutics, Link Health and Pregene expands our geographic reach and demonstrates the global commercial potential of ALLOB,said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. We already have operational experience in Asia with the Phase III clinical trial of our lead product JTA-004 in Hong Kong. We selected Link Health and Pregene to partner with us in Asia as a result of their expertise in advanced therapeutics and cell therapies, their proven track record of development and commercial implementation in Chinese and Asian markets, and Pregenes well established cell therapy manufacturing capacity. Bone Therapeutics will continue to develop the ALLOB cell therapy platform for other markets while exploring additional partnership opportunities in the U.S. and Europe.

The agreement grants Link Health and Pregene exclusive rights to clinically develop and commercialize ALLOB for the treatment of human bone disorders in Greater China, Taiwan, Singapore, South Korea, and Thailand. All rights for China will be transferred to Pregene and Link Health will gain rights for the remaining countries Bone Therapeutics will share its patented proprietary manufacturing expertise for the expansion and differentiation of bone-forming cells and has the option to sell clinical supplies to Link Health and Pregene in preparation for their clinical development of ALLOB.

This collaboration and license agreement for Bone Therapeutics ALLOB provides a strong addition to our pipeline. ALLOB has demonstrated the potential to reduce the recovery time and stimulate bone growth for a variety of bone conditions, and to have a considerable impact on patients lives,said Yan Song, PhD, Chief Executive Officer of Link Health. It is important for Link Health to collaborate with companies that have strong therapeutic product portfolios and entrepreneurial management. This partnership with Bone Therapeutics is a direct result of our shared commitment to appreciate the enormous potential of cell therapy and regenerative medicine.

Pregene now has a flourishing portfolio of CAR-T cell therapy-based cancer treatments. Bone Therapeutics ALLOB provides anallogeneic, off-the-shelf cell therapy that expands our portfolio of cell therapies to include the sizable commercial potential of orthopedics,said Hongjian Li, Co-founder and Chief Executive Officer of Pregene. We expect to be able to leverage our extensive international cell and gene therapy experience to develop Bone Therapeutics ALLOB platform and subsequently launch products in China and Southeast Asian markets.

ALLOB, an allogeneic and off-the-shelf cell therapy product manufactured through a proprietary, scalable production process, consists of human bone-forming cells derived from cultured bone marrow mesenchymal stem cells of healthy adult donors. In preclinical studies ALLOB has shown to reduce healing time in a delayed-union fracture model by half, and has demonstrated good tolerability and signs of efficacy in two Phase IIa studies for two separate indications. The Companys randomized, placebo-controlled, double-blind Phase IIb clinical trial in patients with difficult tibial fractures has received approval from regulatory authorities in six of the seven planned European countries to date, and is expected to enroll the first patient later this year.

About Link Health Pharma Co., Ltd

Link Health is a leading Chinese pharmaceutical company based in Guangzhou, Southern China, focusing on the development of innovative drugs for unmet medical needs.

Link Health has created a highly professional team with diverse expertise in drug development, medical affairs and regulatory affairs. Leveraging deep understanding of China market, regulatory environment and strong network with global biopharmaceutical companies, Link Health is well positioned to bring innovative drugs to the market efficiently. The company has a drug development pipeline of 5 clinical stage assets and 1 under NDA reviewing in China.

The company has also established a fully owned subsidiary in Amsterdam, the Netherlands. The Dutch office builds and further strengthen collaborations with global pharma/biotech partners and research institutes.

About Pregene Biopharma Co., Ltd

Shenzhen Pregene Biopharma Co. Ltd is a leading enterprise in the cell and gene therapy field with the core technology for industrialization. The companys core team comes from well-known institutions and companies including the Academy of Military Medical Sciences, the University of Toronto, and the US FDA.

Pregene has established the gene editing platform, viral vector and cell production platform, nanobody selection platform and other small to pilot trial manufacturing system, with total investment over 100 million CNY. It has the laboratories and GMP plants for cell and gene therapy of over 10,000 square meter.

The company focuses on the research and development of cell and gene therapy drugs, and participated in the drafting the national standard Considerations for CAR-T Cell Quality Study and Non-clinical Evaluation issued by the National Institutes for Food and Drug Control in June 2018. The CAR-T cell therapy for the treatment of multiple myeloma have obtained NMPA IND clearance as the Class I new drug, which is the first in China and fastest in the world using the humanized single domain antibody in CAR construct, and phase I clinical trials are now in progress. Other pipelines such as CAR-T, TCR-T and mRNA drugs for tumors, autoimmune diseases and other indications are in the development at different stages. The company has broad development prospects with the abundant backup technologies.

Looking forward to the future, the company will build the core capacity in one-stop solution for cell and gene therapy drugs, and fulfill the Express of innovative medicine development from drug discovery to clinical products.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.

Bone Therapeutics core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available atwww.bonetherapeutics.com.

For further information, please contact:

Bone Therapeutics SA Miguel Forte, MD, PhD, Chief Executive Officer Jean-Luc Vandebroek, Chief Financial Officer Tel: +32 (0)71 12 10 00 investorrelations@bonetherapeutics.com

For Belgian Media and Investor Enquiries: Bepublic Catherine Haquenne Tel: +32 (0)497 75 63 56 catherine@bepublic.be

International Media Enquiries: Image Box Communications Neil Hunter / Michelle Boxall Tel: +44 (0)20 8943 4685 neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries: NewCap Investor Relations & Financial Communications Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouill Tel: +33 (0)1 44 71 94 94 bone@newcap.eu

For US Media and Investor Enquiries: LHA Investor Relations Yvonne Briggs Tel: +1 310 691 7100 ybriggs@lhai.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Read more from the original source:
Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia -...

Neural Stem Cells Market size and Key Trends in terms of volume and value 2020- – News by aeresearch

Global Neural Stem Cells Market research report provides and in-depth analysis on industry and economy-wide database for business management that could potentially offer development and profitability for players in this market. The Neural Stem Cells market report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, regions, demand and developments.

The Neural Stem Cells market report contains a holistic analysis of this business domain, with respect to the key growth drivers, opportunities, and restraints. The document scrutinizes the impact of COVID-19 pandemic on the growth matrix of this vertical. Moreover, it provides crucial information regarding the competitive landscape and assesses popular tactics employed by leading participants in order to adapt to the market instabilities.

Major highlights from COVID-19 impact analysis:

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/320130

An overview of the regional analysis:

Additional highlights from the Neural Stem Cells market report:

Key Questions Answered:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/320130

Read more here:
Neural Stem Cells Market size and Key Trends in terms of volume and value 2020- - News by aeresearch

NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank – PRNewswire

MINNEAPOLIS, Oct. 6, 2020 /PRNewswire/ --The National Marrow Donor Program (NMDP)/Be The Match today announced a collaboration with the Minnesota health system M Health Fairview and Marcus Center for Cellular Cures (MC3)/Carolinas Cord Blood Bank at Duke University (Duke) to offer cryopreservation services to transplant centers through the Be The Match BioBank. The collaboration brings together industry-leading expertise in cryopreservation and storage of patient-directed donor blood stem cell products to improve donor availability, collection quality, and ultimately, to provide a more reliable path to transplant for patients.

Through the Be The Match BioBank, blood stem cell donors will be able to donate bone marrow or peripheral blood stem cells (PBSC) for an intended patient on a timeline that is convenient for the donor. The cells are then cryopreserved and stored for the transplant center at no cost to them and shipped to coincide with initiation of the patient's conditioning regimen and optimal treatment timeline.

"We're excited to expand our partnership with Duke University by adding the expertise of physicians and researchers at M Health Fairview University of Minnesota Medical Center to continue to overcome logistical barriers to blood and marrow transplantation that might otherwise disrupt optimal patient care. Through the flexibility offered by the Be The Match BioBank, we believe we can provide transplant centers with a well-matched, available donor more often, and allow the transplant to occur at the best time for the patient," explained Steven Devine, MD, Chief Medical Officer, NMDP/Be The Match, and Associate Scientific Director, CIBMTR (Center for International Blood and Marrow Transplant Research). "The team at the Duke University lab was instrumental in the development of the Be The Match BioBank, as well as supporting donor product cryopreservation during the COVID-19 pandemic to ensure patients can continue to receive the transplants they need."

"We are proud to extend our partnership with the NMDP/Be The Match in a new way. Be The Match BioBank is an innovative way to remove barriers that otherwise may stand in the way of a patient's transplant," said Joanne Kurtzberg, MD, who leads the Marcus Center for Cellular Cures (MC3)/Carolinas Cord Blood Bank at Duke University.

"We are thrilled to be working with the NMDP/Be The Match to offer Be The Match BioBank. Through this partnership, transplant physicians can have confidence a high-quality bone marrow or PBSC product will be available from the donor they requested in the timeframe that works best for their patient," said David McKenna, MD, who leads the Molecular and Cellular Therapeutics program at M Health Fairview.

Be The Match BioBank can be used by any transplant center in the NMDP/Be The Match Network of more than 180 transplant centers worldwide. Blood stem cell donors are informed that the transplant center is requesting cryopreservation and provide consent prior to collection. Donors can also consent to having their donated cells made available to other searching patients in the unlikely event the intended patient is unable to proceed to transplant as planned.

To learn more about Be The Match BioBank, visit Network.BeTheMatchClinical.org/BioBank.

About the National Marrow Donor Program/Be The Match The National Marrow Donor Program/Be The Match is the global leader in providing a cure to patients with life-threatening blood and marrow cancers like leukemia and lymphoma, as well as other diseases. The organization manages the world's largest registry of potential blood stem cell donors and cord blood units. The NMDP/Be The Match partners with a global network to connect patients to their donor match for a transplant, and provides education and support for patients. Through Be The Match BioTherapies, the NMDP/Be The Match partners with cell and gene therapy companies to support the development and delivery of new therapies. The organization conducts research through its research program, CIBMTR (Center for International Blood and Marrow Transplant Research), in collaboration with Medical College of Wisconsin.

About M Health Fairview M Health Fairview is the newly expanded collaboration betweenthe University of Minnesota, University of Minnesota Physicians,and Fairview Health Services. The healthcare system combines the best of academic and community medicine expanding access to world-class, breakthrough care through its 10 hospitals and 60 clinics.

SOURCE Be The Match

Read more from the original source:
NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank - PRNewswire

Stem Cell Characterization and Analysis Tool Market Set to Witness an Uptick during 2020 2026 – The Daily Chronicle

The Stem Cell Characterization and Analysis Tool Market study offers a whole investigation of the Industry that contains authenticities, experiences, authentic information, and factually upheld and industry-approved market data. Stem Cell Characterization and Analysis Tool Market report conjointly contains estimates that are gotten from reliable sources and practices.

Stem Cell Characterization and Analysis Tool Industry Segmentation

The whole Stem Cell Characterization and Analysis Tool market has been sub-sorted by segments and subsegments. The report offers an examination of those subsections concerning the provincial division. This market research report can keep marketers refined and assist them in making informed business decisions and gain a competitive edge in the market over their competitors.

The Stem Cell Characterization and Analysis Tool market can be segmented:

By Companies: Osiris Therapeutics, Inc., Cytori Therapeutics, Inc., Astellas Pharma Inc., Caladrius Biosciences, Inc., Cellular Engineering Technologies Inc., U.S. Stem Cell, Inc., BioTime Inc., TEMCELL Technologies Inc., BrainStorm Cell Therapeutics Inc.

By Types: Services, Software, Instruments, Accessories, Consumables, Reagent and Assay Kits

By Application: Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Diabetes, Other Therapeutic Applications, Drug Development and Discovery Embryonic Stem Cells Research

Get Instant Sample [emailprotected] https://www.regalintelligence.com/request-sample/170873

This Stem Cell Characterization and Analysis Tool market report is submitted the far-reaching utilization of both primary and secondary information sources. The market research report incorporates the investigation of numerous components that are impacting the business, along with the govt strategy, current situation and market condition, patterns inside the market, future innovations, and specialized advancement in associated ventures, and market opportunities, market obstructions, and difficulties.

With figures and tables, the report studies the Stem Cell Characterization and Analysis Tool Industry. This investigation conveys key measurements on the condition of the market and could be an important information source for creators and individuals inquisitive about this market. The report conjointly offers late market elements, such as driving factors, limiting elements, and market news, for example, mergers, ventures, and acquisitions. It offers market size (volume and worth), market income, development rate, and incorporates each quantitative and subjective methodologies to make assessments in various districts or nations.

The report on Stem Cell Characterization and Analysis Tool market will help in understanding the business to construct ways for business development in a likely manner. Inside the report, it furthermore offers bits of knowledge from advancing channel to potential development methodologies, giving top to bottom investigation of dominating players in the Stem Cell Characterization and Analysis Tool market.

Enquire about this [emailprotected] https://www.regalintelligence.com/enquiry/170873

1 Report Overview 1.1 Study Scope and Definition 1.2 Research Methodology 1.2.1 Methodology/Research Approach 1.2.2 Data Source 1.3 Key Market Segments 1.4 Players Covered: Ranking by Stem Cell Characterization and Analysis Tool Revenue 1.5 Market Analysis by Type 1.5.1 Global Stem Cell Characterization and Analysis Tool Market Size Growth Rate by Type: 2020 VS 2026 1.5.2 Services 1.5.3 Software 1.5.4 Instruments 1.5.5 Accessories 1.5.6 Consumables 1.5.7 Reagent and Assay Kits 1.6 Market by Application 1.6.1 Global Stem Cell Characterization and Analysis Tool Market Share by Application: 2021-2026 1.6.2 Neurological Disorders 1.6.3 Orthopedic Treatments 1.6.4 Oncology Disorders 1.6.5 Diabetes 1.6.6 Other Therapeutic Applications 1.6.7 Drug Development and Discovery Embryonic Stem Cells Research 1.7 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth 1.7.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections 1.7.2 Covid-19 Impact: Commodity Prices Indices 1.7.3 Covid-19 Impact: Global Major Government Policy 1.8 Study Objectives 1.9 Years Considered 2 Global Stem Cell Characterization and Analysis Tool Market Trends and Growth Strategy 2.1 Market Top Trends 2.2 Market Drivers 2.3 Market Challenges 2.4 Porters Five Forces Analysis 2.5 Market Growth Strategy 2.6 SWOT Analysis 3 Global Stem Cell Characterization and Analysis Tool Market Players Profiles 3.1 Osiris Therapeutics, Inc. 3.1.1 Osiris Therapeutics, Inc. Company Profile 3.1.2 Osiris Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.1.3 Osiris Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.2 Cytori Therapeutics, Inc. 3.2.1 Cytori Therapeutics, Inc. Company Profile 3.2.2 Cytori Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.2.3 Cytori Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.3 Astellas Pharma Inc. 3.3.1 Astellas Pharma Inc. Company Profile 3.3.2 Astellas Pharma Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.3.3 Astellas Pharma Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.4 Caladrius Biosciences, Inc. 3.4.1 Caladrius Biosciences, Inc. Company Profile 3.4.2 Caladrius Biosciences, Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.4.3 Caladrius Biosciences, Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.5 Cellular Engineering Technologies Inc. 3.5.1 Cellular Engineering Technologies Inc. Company Profile 3.5.2 Cellular Engineering Technologies Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.5.3 Cellular Engineering Technologies Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.6 U.S. Stem Cell, Inc. 3.6.1 U.S. Stem Cell, Inc. Company Profile 3.6.2 U.S. Stem Cell, Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.6.3 U.S. Stem Cell, Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.7 BioTime Inc. 3.7.1 BioTime Inc. Company Profile 3.7.2 BioTime Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.7.3 BioTime Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.8 TEMCELL Technologies Inc. 3.8.1 TEMCELL Technologies Inc. Company Profile 3.8.2 TEMCELL Technologies Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.8.3 TEMCELL Technologies Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.9 BrainStorm Cell Therapeutics Inc. 3.9.1 BrainStorm Cell Therapeutics Inc. Company Profile 3.9.2 BrainStorm Cell Therapeutics Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.9.3 BrainStorm Cell Therapeutics Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 4 Global Stem Cell Characterization and Analysis Tool Market Competition by Market Players 4.1 Global Stem Cell Characterization and Analysis Tool Production Capacity Market Share by Market Players (2015-2020) 4.2 Global Stem Cell Characterization and Analysis Tool Revenue Market Share by Market Players (2015-2020) 4.3 Global Stem Cell Characterization and Analysis Tool Average Price by Market Players (2015-2020) 5 Global Stem Cell Characterization and Analysis Tool Production by Regions (2015-2020) 5.1 North America 5.1.1 North America Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.1.2 Stem Cell Characterization and Analysis Tool Key Players in North America (2015-2020) 5.1.3 North America Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.1.4 North America Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.2 East Asia 5.2.1 East Asia Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.2.2 Stem Cell Characterization and Analysis Tool Key Players in East Asia (2015-2020) 5.2.3 East Asia Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.2.4 East Asia Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.3 Europe 5.3.1 Europe Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.3.2 Stem Cell Characterization and Analysis Tool Key Players in Europe (2015-2020) 5.3.3 Europe Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.3.4 Europe Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.4 South Asia 5.4.1 South Asia Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.4.2 Stem Cell Characterization and Analysis Tool Key Players in South Asia (2015-2020) 5.4.3 South Asia Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.4.4 South Asia Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.5 Southeast Asia 5.5.1 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.5.2 Stem Cell Characterization and Analysis Tool Key Players in Southeast Asia (2015-2020) 5.5.3 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.5.4 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.6 Middle East 5.6.1 Middle East Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.6.2 Stem Cell Characterization and Analysis Tool Key Players in Middle East (2015-2020) 5.6.3 Middle East Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.6.4 Middle East Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.7 Africa 5.7.1 Africa Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.7.2 Stem Cell Characterization and Analysis Tool Key Players in Africa (2015-2020) 5.7.3 Africa Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.7.4 Africa Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.8 Oceania 5.8.1 Oceania Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.8.2 Stem Cell Characterization and Analysis Tool Key Players in Oceania (2015-2020) 5.8.3 Oceania Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.8.4 Oceania Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.9 South America 5.9.1 South America Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.9.2 Stem Cell Characterization and Analysis Tool Key Players in South America (2015-2020) 5.9.3 South America Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.9.4 South America Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.10 Rest of the World 5.10.1 Rest of the World Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.10.2 Stem Cell Characterization and Analysis Tool Key Players in Rest of the World (2015-2020) 5.10.3 Rest of the World Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.10.4 Rest of the World Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 6 Global Stem Cell Characterization and Analysis Tool Consumption by Region (2015-2020) 6.1 North America 6.1.1 North America Stem Cell Characterization and Analysis Tool Consumption by Countries 6.1.2 United States 6.1.3 Canada 6.1.4 Mexico 6.2 East Asia 6.2.1 East Asia Stem Cell Characterization and Analysis Tool Consumption by Countries 6.2.2 China 6.2.3 Japan 6.2.4 South Korea 6.3 Europe 6.3.1 Europe Stem Cell Characterization and Analysis Tool Consumption by Countries 6.3.2 Germany 6.3.3 United Kingdom 6.3.4 France 6.3.5 Italy 6.3.6 Russia 6.3.7 Spain 6.3.8 Netherlands 6.3.9 Switzerland 6.3.10 Poland 6.4 South Asia 6.4.1 South Asia Stem Cell Characterization and Analysis Tool Consumption by Countries 6.4.2 India 6.5 Southeast Asia 6.5.1 Southeast Asia Stem Cell Characterization and Analysis Tool Consumption by Countries 6.5.2 Indonesia 6.5.3 Thailand 6.5.4 Singapore 6.5.5 Malaysia 6.5.6 Philippines 6.6 Middle East 6.6.1 Middle East Stem Cell Characterization and Analysis Tool Consumption by Countries 6.6.2 Turkey 6.6.3 Saudi Arabia 6.6.4 Iran 6.6.5 United Arab Emirates 6.7 Africa 6.7.1 Africa Stem Cell Characterization and Analysis Tool Consumption by Countries 6.7.2 Nigeria 6.7.3 South Africa 6.8 Oceania 6.8.1 Oceania Stem Cell Characterization and Analysis Tool Consumption by Countries 6.8.2 Australia 6.9 South America 6.9.1 South America Stem Cell Characterization and Analysis Tool Consumption by Countries 6.9.2 Brazil 6.9.3 Argentina 6.10 Rest of the World 6.10.1 Rest of the World Stem Cell Characterization and Analysis Tool Consumption by Countries 7 Global Stem Cell Characterization and Analysis Tool Production Forecast by Regions (2021-2026) 7.1 Global Forecasted Production of Stem Cell Characterization and Analysis Tool (2021-2026) 7.2 Global Forecasted Revenue of Stem Cell Characterization and Analysis Tool (2021-2026) 7.3 Global Forecasted Price of Stem Cell Characterization and Analysis Tool (2021-2026) 7.4 Global Forecasted Production of Stem Cell Characterization and Analysis Tool by Region (2021-2026) 7.4.1 North America Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.2 East Asia Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.3 Europe Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.4 South Asia Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.5 Southeast Asia Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.6 Middle East Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.7 Africa Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.8 Oceania Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.9 South America Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.10 Rest of the World Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.5 Forecast by Type and by Application (2021-2026) 7.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026) 7.5.2 Global Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Application (2021-2026) 8 Global Stem Cell Characterization and Analysis Tool Consumption Forecast by Regions (2021-2026) 8.1 North America Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.2 East Asia Market Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.3 Europe Market Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Countriy 8.4 South Asia Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.5 Southeast Asia Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.6 Middle East Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.7 Africa Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.8 Oceania Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.9 South America Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.10 Rest of the world Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 9 Global Stem Cell Characterization and Analysis Tool Sales by Type (2015-2026) 9.1 Global Stem Cell Characterization and Analysis Tool Historic Market Size by Type (2015-2020) 9.2 Global Stem Cell Characterization and Analysis Tool Forecasted Market Size by Type (2021-2026) 10 Global Stem Cell Characterization and Analysis Tool Consumption by Application (2015-2026) 10.1 Global Stem Cell Characterization and Analysis Tool Historic Market Size by Application (2015-2020) 10.2 Global Stem Cell Characterization and Analysis Tool Forecasted Market Size by Application (2021-2026) 11 Global Stem Cell Characterization and Analysis Tool Manufacturing Cost Analysis 11.1 Stem Cell Characterization and Analysis Tool Key Raw Materials Analysis 11.1.1 Key Raw Materials 11.2 Proportion of Manufacturing Cost Structure 11.3 Manufacturing Process Analysis of Stem Cell Characterization and Analysis Tool 12 Global Stem Cell Characterization and Analysis Tool Marketing Channel, Distributors, Customers and Supply Chain 12.1 Marketing Channel 12.2 Stem Cell Characterization and Analysis Tool Distributors List 12.3 Stem Cell Characterization and Analysis Tool Customers 12.4 Stem Cell Characterization and Analysis Tool Supply Chain Analysis 13 Analyst's Viewpoints/Conclusions 14 Disclaimer

Get Detailed Table of Contents: https://www.regalintelligence.com/request-toc/170873

The report contains Porters 5 Forces Model, Value Chain Analysis, and Market Pull Analysis. These devices encourage to get a straightforward picture of the business structure and evaluate the market quality at a global level. Moreover, these apparatuses conjointly present a total investigation of product application inside the worldwide Stem Cell Characterization and Analysis Tool Industry.

Here is the original post:
Stem Cell Characterization and Analysis Tool Market Set to Witness an Uptick during 2020 2026 - The Daily Chronicle

Cutting off H-1B visas will hurt the biopharma industry – STAT – STAT

Ive traveled the world because of science.

My undergraduate and doctoral studies were in Boston. Ive done stem cell research in Singapore. I worked in Belgium to learn about camelid antibodies, studied chemistry in England, and given talks around the world.

This type of freedom to study and work across countries made it possible for me to learn from the best, expanded my scientific horizons, and instilled in me a deep passion to make the world a better place. These experiences also empowered me with the skills and conviction needed to enter the biopharma world and start Olaris, a precision medicine company that identifies biomarkers of response to optimize outcomes and improve health.

advertisement

Proposals by the federal government to make it difficult for people of other countries to have these experiences here in the U.S. will, I believe, hurt the biopharmaceutical industry.

In June, Presidential Proclamation 10051 suspended immigration into the United States for anyone holding H-1B, J-1, and L visas, and suspended granting new ones. Most worrisome for the pharmaceutical industry is the ban on H-1B visas, because it will limit, and in some instances entirely prevent, biopharma companies from recruiting the specialized talent they need.

advertisement

According to the proclamation, the suspension and limitation are aimed at ensuring that the presence in the United States of H-1B nonimmigrants does not disadvantage United States workers. The proclamation ends on Dec. 31, at which point the limitations will cease or the administration may extend them as it sees fit.

In August, the president issued an executive order that prevents federal agencies from hiring employees that would displace American workers. This would require federal employers to prove that a new employee requiring an H-1B visa would not be replacing an American worker. Federal agencies like the National Institute of Health, the National Science Foundation, the Department of Defense, and the Food and Drug Administration have multiple million- to billion-dollar research budgets and typically employ hundreds of talented scientists, including U.S. citizens and, at least until now, many through H-1B sponsorship. Federal funded research is an essential part of the science and innovation ecosystem and in many ways acts as a feeder to biopharma for ideas, tools, and people. So, while this may not seem to directly hurt biopharma immediately, it will cut off important pipelines.

And in September, the Department of Homeland Security submitted to the Office of Management and Budget a new H-1B regulation for final review that further restricts the definition of specialty occupation and makes it more difficult for visa holders who work primarily outside of the main office. For biopharma companies this could have dual repercussions. It could limit staff being sent out to the field, such as hospitals, manufacturing sites, and the like. It could also limit the staffing of many of service providers, such as IT, maintenance, sanitation, and health and safety specialists who are engaged to work in biopharma facilities. This new regulation is designated as an interim final rule, meaning it will go into effect immediately without public input.

Science is global work, and the biopharma industry is a global business. Biopharma companies need to have the ability to hire the most qualified candidate for a particular job regardless of where that person was born and raised.

The biggest biopharma companies, such as Novartis, Sanofi, Pfizer, Amgen, and others, hire many talented workers via H-1B sponsorship to develop therapies. So do small companies like mine: Two of our 12 employees have H-1B visas.

A recent commentary on U.S. immigration policies in the journal Cell showed that immigrants were drivers to many breakthrough therapies such as Avastin, which helps individuals with molecular degeneration see better; Remicade, which makes it easier for rheumatoid arthritis patients to walk; CAR-T cell therapies that can bring long-term remission to many cancer patients; and more.

Even our hope for a Covid-19 vaccine can be tied to the work of immigrants: The founders of Moderna, one of the forerunners in vaccine development, include Derrick Rossi, a Canadian who originally came to Stanford for a postdoctoral fellowship on an H-1B visa, and Noubar Afeyan, who was an international Ph.D. student at the Massachusetts Institute of Technology. Even Stphane Bancel, Modernas CEO, was once an international student at Minnesota and at Harvard Business School.

If we want more innovation and we need it we cant limit the talent pool.

Covid-19 has killed more than 200,000 people in the U.S alone, put millions of Americans out of work, and is crushing local economies. I understand the desire to boost employment for Americans. Yet the logic that limiting H-1B visas will let more American citizens get jobs doesnt make sense for biopharma companies because there arent enough Americans trained at the highest levels of science to fill the existing job openings.

American universities are training the best and the brightest in the sciences, and the majority of those trainees are foreigners. The National Foundation for American Policy reported in 2017 that 79% of students in computer science, 57% in chemical engineering, and 56% in pharmaceutical sciences at U.S. institutions were international students. If our federal government wants citizens to be more competitive for todays biopharma jobs, it must do more to improve science, technology, engineering, and mathematics education and encourage more youths to pursue it.

Many international students who train in the U.S. want to stay here, rent or buy homes, dine at restaurants, shop at local stores, participate in our economy, become active members of the community, and even pay taxes, all while contributing to scientific discoveries with the potential to transform society or at least they used to. If visas become limited and they cant find jobs, they will seek biopharma jobs elsewhere.

If the U.S. continues on its current H-1B path, biopharma companies who cannot hire the workers they need will be faced with a few choices: Establish new hubs abroad or move main offices to other countries, outsource the work when possible to service providers in other countries, or decide against pursuing the work altogether. None of these choices seem nearly as good for the companies, or the U.S. economy, as bringing on additional full-time workers. Denying H-1B visas is bad economics and bad for science.

The biopharma industry is an essential part of the U.S economy and a key player in addressing the Covid-19 crisis. We need representatives who will craft legislation that will bolster, not hinder, biopharmas efforts. More than ever we need the best science done by the best scientists, and that knows no boundaries.

Elizabeth ODay is the founder and CEO of Massachusetts-based Olaris. This essay was adapted from a longer version that was originally published on the Olaris website.

Trending

Race for Covid-19 vaccine slows as regulators, top Warp

Race for Covid-19 vaccine slows as regulators, top Warp Speed official tap the brakes

As AstraZenecas Covid-19 vaccine trial remains on hold in

As AstraZenecas Covid-19 vaccine trial remains on hold in U.S., participants waiting on a second dose

CDC: 80,000 people died of flu last winter in

CDC: 80,000 people died of flu last winter in U.S., highest death toll in 40 years

Recommended

Is it cant hurt the rationale for giving Trump

Is it cant hurt the rationale for giving Trump unproven Covid-19 treatments?

Access to medical oxygen: a glaring global inequity

Access to medical oxygen: a glaring global inequity

The irony of the day: Covid-19 at the White

The irony of the day: Covid-19 at the White House is a simple matter of workplace

Read the original post:
Cutting off H-1B visas will hurt the biopharma industry - STAT - STAT

Oncology Market Size 2020 Particularly Prone To Disruption During Pandemic In The Global Oncology Market – GlobeNewswire

October 06, 2020 06:00 ET | Source: The Business Research Company

LONDON, Oct. 06, 2020 (GLOBE NEWSWIRE) -- (Oncology Drugs Companies Included: F. Hoffmann-La Roche AG, Novartis AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Johnson & Johnson)

The global oncology/cancer drugs market size reached a value of nearly $167.9 billion in 2019, having increased at a compound annual growth rate (CAGR) of 9.8% since 2015. The oncology market size 2020 is expected to decline from $167.9 billion in 2019 to $149.9 billion in 2020 at a rate of -11%. The decline is mainly due to lockdown and social distancing norms imposed by various countries and economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it. The market is then expected to grow slightly from $201.1 billion in 2021 to $284.5 billion in 2023 at a CAGR of 9.7%. North America has the largest cancer drug market share, accounting for 41.2% of the total market.

The Business Research Companys report titled Oncology Drugs Market - Opportunities And Strategies - Global Forecast To 2030 covers major oncology drugs companies, oncology drugs market share by company, oncology drugs manufacturers, oncology drugs infrastructure market size, and oncology drugs market forecasts. The report also covers the global oncology drugs market and its segments. The cancer market by type is segmented into drugs for lung cancer, pancreatic cancer, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric cancer, kidney cancer, brain tumor, thyroid cancer, skin cancer, bladder cancer, cervical cancer, blood cancer and others, by drug class type into targeted therapy, immunotherapy (biologic therapy), chemotherapy and hormonal therapy, by distribution channel into hospital pharmacies, retail pharmacies/drug stores and others, by route of administration into oral, parental and others, by drug classification into branded drugs and generic drugs.

Request For A Sample Of The Global Oncology Drugs Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3440&type=smp

Companies in the oncology drugs market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, organizations are developing innovative products as well as sharing skills and expertise with other such enterprises. While oncology drug companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years.

New technologies are being implemented in the cancer drug market, such as artificial intelligence in the research and development process, as well as 3D printing devices to mimic the human body for trials and testing of the drugs developed. Companies are also investing in technologies to develop next generation biologics such as antibody drug conjugates, bispecifics, fusion proteins, cell and gene therapy that will be more effective as they are expected to have better potency against the target disease as well as have the ability to treat more than one aspect of the disease. Over the last few years, there has been a significant rise in accelerated approval of cell and gene therapies for cancer treatment by regulatory bodies across the globe. CRISPR technology can be used to discover the non-coding cancer genome. CRISPR-Cas9 genome editing reduces the processing associated with the generation of cell line and animal models of cancer and complex generations. Thus, it generates a better cancer model for target validation and drug evaluation. CRISPRCas9 is accelerating the different stages of oncology drug discovery including target identification, validation and deconvolution, drug synthesis, assessment of drug sensitivity and resistance.

With innovation through technology and rising focus on development of new drugs, the oncology drugs market trends ought to bring advances in cancer therapies in the forecasted period.

Oncology Drugs Market - Opportunities And Strategies - Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provide oncology drugs market overviews, oncology drugs market analyze and forecast oncology drugs market size and growth for the whole market, oncology drugs market segments and oncology drugs market geographies, oncology drugs market trends, oncology drugs market drivers, oncology drugs market restraints, oncology drugs market leading competitors revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies.

The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors approaches.

Here Is A List Of Similar Reports By The Business Research Company:

Clinical Oncology Next Generation Sequencing Global Market Report 2020-30: COVID 19 Growth and Change

Interventional Oncology Devices Global Market Report 2020-30: COVID 19 Growth and Change

Cancer Diagnostics Global Market Report 2020-30: COVID 19 Growth And Change

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The Worlds Most Comprehensive Database

The Business Research Companys flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

Link:
Oncology Market Size 2020 Particularly Prone To Disruption During Pandemic In The Global Oncology Market - GlobeNewswire

Hemogenyx Pharmaceuticals PLC Announces SAFE-HEMO-CAR-T Effective against AML in vitro – BioSpace

LONDON, UK / ACCESSWIRE / October 6, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce the following update on its activities.

As previously announced, Hemogenyx Pharmaceuticals' CDX bi-specific antibody has the potential to treat Acute Myeloid Leukemia ("AML") directly as well as to provide a benign conditioning regimen for blood stem cell replacement therapy. The Company has now carried out extensive work developing treatments for AML and has to date obtained encouraging results.

As announced on 20 February 2020, the Company has constructed and successfully tested in vivo Chimeric Antigen Receptor ("CAR") programmed T cells ("HEMO-CAR-T") for the potential treatment of AML. HEMO-CAR was constructed using the Company's proprietary humanized monoclonal antibody against a target on the surface of AML cells.

It was also announced that the Company was engaging in additional engineering of HEMO-CAR-T cells to increase their safety and versatility. The Company has now introduced and successfully in vitro tested a safety switch within the HEMO-CAR. The aim of this safety switch is to modulate the activity of HEMO-CAR-T cells and to turn them into a "controllable drug" - SAFE-HEMO-CAR-T. The purpose of these efforts is to dramatically improve the safety and potential versatility of HEMO-CAR-T cells for the treatment of AML and/or conditioning of bone marrow transplants, as well as a number of additional potential indications.

Following the successful completion of these in vitro tests, in vivo tests of the efficacy of SAFE-HEMO-CAR-T against AML are being conducted using a model of AML established on the background of Advanced peripheral blood Hematopoietic Chimera (ApbHC) - humanized mice developed by Immugenyx, LLC, a subsidiary of Hemogenyx Pharmaceuticals. If these in vivo tests are successful, the Company will discuss its findings with its partners under the Sponsored Research Agreement with the University of Pennsylvania, announced on 11 August 2020, with a view to considering the inclusion of SAFE-HEMO-CAR-T in the program of pre-clinical trials currently underway there.

Dr Vladislav Sandler, Chief Executive Officer, commented, "We are encouraged by this new data which demonstrates our continuing progress in the development of novel treatments for blood cancers such as AML. The development of SAFE-HEMO-CAR-T further expands the Company's pipeline and advances it into a cutting-edge area of cell-based immune therapy. We are excited to have developed another unique product candidate that should, if successful, provide a new and potentially effective treatment for blood cancers for which survival rates are currently very poor."

About AML and CAR-T

AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 25% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease.

CAR-T therapy is a treatment in which a patient's own T cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T cells from the patient, modifying the isolated T cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Enquiries:

Hemogenyx Pharmaceuticals plc

Home

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit http://www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com: https://www.accesswire.com/609275/Hemogenyx-Pharmaceuticals-PLC-Announces-SAFE-HEMO-CAR-T-Effective-against-AML-in-vitro

Read more:
Hemogenyx Pharmaceuticals PLC Announces SAFE-HEMO-CAR-T Effective against AML in vitro - BioSpace

Reven Strengthens Its Clinical Team With Three New Members – BioSpace

Oct. 5, 2020 11:30 UTC

GOLDEN, Colo.--(BUSINESS WIRE)-- Reven Holdings, Inc. (Reven) is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnessesincluding COVID-19and inflammatory disorders.

Reven is planning to initiate a randomized, double-blind, placebo-controlled, multi-institutional clinical trial of its lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19. The upcoming clinical trial is designed to evaluate the safety and efficacy of RJX in COVID-19 patients.

Reven today announced that three new members with extensive experience and knowledge in clinical research and quality assurance have joined its multi-disciplinary team to work on the COVID-19 clinical project:

Nancy Oehlke has assumed the role of Manager of Regulatory Affairs and Quality Assurance. Nancy has 20+ years of experience in drug development, Good Manufacturing Practice (GMP) / Good Laboratory Practice (GLP) compliance, regulatory aspects of drug product manufacturing and testing, and clinical research.

Renae Townsend has assumed the role of Director of Clinical Operations and Jenny Daniels has assumed the role of Director of Clinical Quality Assurance. Both Renae and Jenny have 15+ years of Good Clinical Practice (GCP), clinical research and clinical monitoring experience.

These new team members will help us provide sponsor oversight for the services rendered by the clinical research organizations (CRO) and other vendors who will support our clinical RJX program and execution of the clinical trial. I am excited to welcome these very experienced new members to Reven. I look forward to the opportunity to work side by side with them as we try to diligently advance the clinical development of RJX, said Fatih Uckun, MD PhD, Chief Medical Officer and Chief Scientific Officer of Reven.

Our IND (Investigational New Drug) application package for COVID-19 is completed and we are planning to roll out our clinical program against COVID-19 in the coming month, said Michael Volk, Director and Chief Strategy Officer of Reven.

Our new team members each will have a very important role in our efforts aimed at evaluating the clinical impact potential of RJX, added Peter Lange, CEO of Reven.

About Rejuveinix (RJX) RJX is an intravenous (IV) formulation of a patented first-in-class pharmaceutical composition containing a specific mixture of anti-oxidant and anti-inflammatory ingredients that is being developed for more effective treatment of patients with inflammatory disorders, including COVID-19 patients with viral sepsis and acute respiratory distress syndrome (ARDS). The clinical safety and tolerability of RJX was confirmed in a recently completed double blind, placebo-controlled Phase 1 dose-escalation study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105).

About Reven Holdings, Inc. Reven Holdings, Inc., a Delaware corporation, through its Golden/Colorado-based operating company Reven, LLC, is developing new drugs for difficult-to-treat diseases. As a clinical stage biopharmaceutical company, Revens overarching goal is to develop effective treatments for serious health conditions caused by infectious, inflammatory, cardiovascular, and metabolic diseases. Its lead product, RJX, is being developed as a treatment platform against complications of COVID-19, sepsis, cardiovascular diseases, and diabetes.

About Dr. Fatih Uckun, M.D., Ph.D, Chief Medical Officer of Reven. Dr. Uckun is an Active Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations. He earned his doctoral degrees at University of Heidelberg in Germany and completed his residency training in Pediatrics, fellowship training in Hematology/Oncology/Blood and Bone Marrow Stem Cell Transplantation, as well as postdoctoral research training in immunology and microbiology at the University of Minnesota in the US.

Dr. Uckun has more than 30 years of professional experience in developmental therapeutics and biopharmaceuticals in oncology/immuno-oncology as well as infectious diseases and immunology. In addition, Dr. Uckun has deep knowledge and 20+ years of experience in treatment of infectious diseases and their complications. In particular, he has extensive experience in viral, fungal, and bacterial infections of immunocompromised hosts, septic shock, ARDS as well as systemic capillary leak syndrome and cytokine release syndrome (CRS). Dr. Uckun served as a Defense Advanced Research Projects Agency (DARPA)-funded principal investigator and directed a universal virus neutralizer program project as part of a countermeasures initiative against viruses that can be used as bioweapons and therefore pose a biothreat for our national security. Prior to joining Reven, Dr. Uckun was a Vice President, Clinical Strategy Lead, Oncology-Hematology and Member of the COVID-19 Task Force at Worldwide Clinical Trials.

Dr. Uckun worked 11 years as a Professor of Bone Marrow Transplantation, Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota, where he became the first recipient of the Endowed Hughes Chair in Biotherapy. He worked 6 years as a Professor and Head of Translational Research in Leukemia and Lymphoma of the CCBD and a Principal Investigator of the Stem Cell-Regenerative Medicine Initiative at the at the University of Southern California. During that time, Dr. Uckun served as the Chair of the Biotargeting Working Group for the National Cancer Institute (NCI)s Nanotechnology Alliance in Cancer.

He has held executive positions in multiple biotechnology companies and has extensive regulatory experience. He has published more than 500 peer-reviewed papers, received numerous awards, and served as a member of several medical journal editorial boards and NIH grant review/special emphasis panels. Website: https://www.linkedin.com/in/fatihuckun/

Revens Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as may, on-track, expect, anticipate hope, vision, optimism, design, exciting, promising, will, conviction, estimate, intend, believe and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the companys product candidates and the potential use of the companys product candidates to treat various disease indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing market competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates, and unexpected litigation or other disputes. These risks are not exhaustive; the company faces known and unknown risks, including the risk factors described in the companys periodic SEC filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information regarding future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005298/en/

Link:
Reven Strengthens Its Clinical Team With Three New Members - BioSpace

Two top execs in Sanofi’s R&D group are hitting the exit in a shakeup as Frank Nestle moves up to CSO – Endpoints News

Three years ago, Jennifer Doudna gathered with two postdocs and a fellow biochemist around a circular table on the second floor of UC Berkelys Energy Biosciences building, where they tried to answer a question: What, precisely, would the best gene editor look like?

By that point, a slate of startups had launched to turn CRISPR-Cas9 into drugs, diagnostics and crops. But researchers at Berkeley and elsewhere were turning up new enzymes that were smaller, more versatile than the original Cas9 enzymes that, if engineered correctly, could solve some of the challenges early CRISPR research had faced. They decided to take one of them, called CasX, and try to use it in an area that had long been black hole for both pharma neurodegeneration.

Unlock this story instantly and join 91,100+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Original post:
Two top execs in Sanofi's R&D group are hitting the exit in a shakeup as Frank Nestle moves up to CSO - Endpoints News